id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-262029-zzn74cjr	Kang, Chang Kyung	In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses	2020-05-29		.txt	text/plain	2575	151	52	We examined the in vitro activity of lopinavir/ritonavir and hydroxychloroquine on SARS-CoV-2, at concentrations which can be used to treat coronavirus-19 patients with little concern of toxicity. Its in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative virus of COVID-19, has been recently suggested [4] . Therefore, the screening of poten-tial antivirals to fight COVID-19 is urgently needed and led us to assess the in vitro activity of lopinavir/ritonavir and hydroxychloroquine on SARS-CoV-2 at clinically administrable doses. We examined the in vitro activity of the oral antivirals lopinavir/ritonavir and hydroxychloroquine against SARS-CoV-2 at their patient administrable doses. In conclusion, this in vitro experimental study showed that lopinavir/ritonavir, at its clinically relevant concentration, showed significant anti-SARS-CoV-2 activity when it was administered following viral infection. 1. Lopinavir/ritonavir showed significant anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) activity both in terms of the prevention of cytotoxicity and reducing the viral load at plasma concentrations achievable by usual doses.	./cache/cord-262029-zzn74cjr.txt	./txt/cord-262029-zzn74cjr.txt